Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors

Acta Cardiologica

Volumn 62, Issue 4, 2007, Pages 321-328

  Gremmler, Bernhard ^a,c   Kisters, Klaus ^b   Kunert, Matthias ^a   Schleiting, Heinrich ^a   Ulbricht, Ludger J ^a,c  

^a Marien Hospital Bottrop gGmbH   (Germany)

^b ST ANNA HOSPITAL   (Germany)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

ACE inhibitors; Beta blockers; Chronic severe heart failure; Selective angiotensin II AT I receptor antagonists

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; TELMISARTAN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CARDIOGRAPHY; CHRONIC PATIENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HEART FAILURE; HEART OUTPUT MEASUREMENT; HEMODYNAMIC MONITORING; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; VASCULAR RESISTANCE;

ACRYLATES; ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIAC OUTPUT; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HEART RATE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TETRAZOLES; THIOPHENES; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 34548183818     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.62.4.2022274     Document Type: Article

References (53)

1. Stewart S, MacIntyre K, Hole D, Capewell S, Mc Murray J. More "malignant" than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Failure 2001; 3: 315-22.
2. McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs R, Maggioni A, Pina I, Soler-Soler J, Swedberg K. Practical recommendations for the use of ACE inhibitors, beta-blockers and spirono-lactone in heart failure: putting guidelines into practice. Eur J Heart Failure 2001; 3: 495-502.
3. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-35.
4. Erdmann E. Indications for ACE inhibitors in chronic heart failure [in German]. Z Kardiol 1994; 83, Suppl 4: 75-9.
5. Hopf R. Prognoseverbesserung mit ACE-Hemmern bei kardialer Dysfunktion: Neue Erkenntnisse durch die AIRE-Studie. Medikon Verlag, München, 1993.
6. Huber K, Pachinger O, Pichler M, Klein W. Pathophysiological mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases [in German]. Z Kardiol 1997; 86: 239-50.
7. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens B. Cardioprotective effects by ramipril after ischemia and reperfusion in animal experiment studies [in German]. Z Kardiol 1994; 83 Suppl 4: 53-6.
8. Pfeffer MA, Braunwald E, Moye'L, Basta L, Brown E, Cuddy T, Davus B, Geltman E, Goldman S, Flaker G. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-77.
9. SOLVD Investigators. Effekt of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-9.
10. Brunner-La Rocca HP, Weilenmann D, Kiowski W, Maly FE, Candinas R, Follath F. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Am Heart J 1999; 138: 654-62.
11. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wilkstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselmann DH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. J Am Med Assoc 2000; 283: 1295-302.
12. The CAPRICORN Investigators. Effects of cardevilol on outcome after myocardial infarct in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-90.
13. Schachter M. ACE inhibitors, angiotensin receptor antagonists and bradykinin. J Renin Angiotensin Aldosterone Syst 2000; 1: 27-9.
14. Bönner G. Bedeutung der Kinine für die Wirkung der ACE-Hemmer. In: Dominiak P, Bönner G, eds. ACE-Hemmer in Klinik und Praxis, Springer-Verlag Berlin-Heidelberg 1995: pp. 37-54.
15. Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Herras M, Sanz G. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000; 21: 53-7.
16. Hanon S, Vijayaraman P, Sonnenblick EH, LeJemtel TH. Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure. J Renin Angiotensin Aldosterone Syst 2000; 1: 147-50.
17. Nussberger J, Juillerat L, Perret F, Waeber B, Bellet M, Brunner J, Menard J. Need for plasma angiotensin measurements to investigate converting-enzyme inhibition in humans. Am Heart J 1989; 117(3): 712-22.
18. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation 1994; 89: 493-8.
19. Dendorfer A, Simon M, Dominiak P. Cardioactive hormones: bradykinin [in German]. Z Kardiol 1996; 85 Suppl 6: 211-8.
20. Dominiak P, Dendorfer A. Pharmakologie und klinische Pharmakologie der AT1-Rezeptorantagonisten. In: Dominiak P, Unger Th, eds. AT1- Rezeptorantagonisten Angiotensin II. Steinkopff Verlag Darmstadt 1997; pp. 41-73.
21. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153: 937-42.
22. Schieffer B, Drexler H. Pathophysiologie der chronischen Herzinsuffizienz. In: Dominiak P, Unger Th, eds. AT1-Rezeptorantagonisten Angiotensin II. Steinkopff Verlag Darmstadt 1997; pp. 129-37.
23. Califf RM, Cohn JN. Cardiac protection: evolving role of angiotensin receptors blockers. Am Heart J 2000; 139 (1Pt 2): 15-22.
24. Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 1993; 11 Supplement 3: S 13-8.
25. Griendling KK, Lassegue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 1996; 36: 281-306.
26. Regitz-Zagrosek V, Neuß M, Warnecke C, Holzmeister J, Hildebrand AG, Fleck E. Angiotensin receptors - organ and subtype specific regulation in cardiovascular diseases by modulation of the renin-angiotensin system. Studies of the rat model and in human myocardium. Z Kardiol 1995; 84 Suppl 4: 61-9.
27. Timmermans P, Wong P, Chiu A, Herblin W, Benfield P, Carini D, Lee R, Wrexler R, Saye JA, Smith R. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45(2): 205-51.
28. Parker AB, Azevedo ER, Baird MG, Smith S, Arnold J, Humen D, Moe G, Parker JO, Butt R, Parker JD. ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada. Am Heart J 1999, 138: 843-8.
29. Willenbrock R Philipp S, Mitrovic V, Dietz R. Neurohumoral blockade in CHF management. J Renin Angiotensin Aldosterone Syst 2000; 1(suppl 1): 24-30.
30. Ohlstein E, Brooks D, Feuerstein G, Ruffalo R. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: Possible relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997; 55: 244-52.
31. Packer M. The neurohormonal hypothesis: a theory to explain the mechanisms of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-54.
32. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55.
33. Pizzulli L, Lüderitz B. Secondary prevention of coronary artery disease [in German]. Dtsch Arztebl 1998; 95 (issue 27): A-1732-1738.
34. Sigmund M, Hanrath P. Beta receptor blockers in chronic heart failure [in German]. Z Kardiol 1995; 84: 820-6.
35. de Gasparo M, Hess P, Nuesslein-Hildesheim B, Bruneval P, Clozel JP. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction. J Renin Angiotensin Aldosterone Syst 2000; 1: 151-8.
36. Shen YT, Wiedmann RT, Greenland BD, Lynch JJ, Grossmann W. Combined effects of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism in conscious pigs with congestive heart failure. Cardiovasc Res 1998; 39(2): 413-22.
37. Weidenbach R, Schulz R, Gres P, Behrends M, Post H, Heusch G. Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT1-receptor antagonism. Brit J Pharmacol 2000; 131: 138-44.
38. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short-and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-Heft) Study Group. Circulation 1999; 99: 2658-64.
39. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Olivari M, Thomas S, LeJemtel T. Addition of angiotensin II receptor blockade to maximal angiotensin converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999; 99: 990-2.
40. Gremmler B, Kunert M, Schleiting H, Ulbricht LJ. Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1 antagonist eprosartan. Eur J Heart Failure 2000; 2: 183-7.
41. Weinberg M, Weinberg A, Zappe D. Effectively targeting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using Angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. J Renin Angiotensin Aldosterone Syst 2000; 1: 217-33.
42. Cohn JN, Tognoni G, Glazer RD, Sporman D, Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999; 5: 155-60.
43. Pitt B, Poole-Wilson P, Segal R, Martinez F, Dickstein K, Camm A, Kostam M, Riegger G, Klinger G, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival study ELITE II. Lancet 2000; 355: 1582-7.
44. Swedberg K, Pfeffer M, Granger C, Held P, McMurry J, Ohlin G, Olofsson B, Ostergren J, Yusuf S. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail 1999; 5: 276-82.
45. Pfeffer MA. Enhancing cardiac protection after myocardial infarction: Rationale for newer clinical trials of angiotensin receptor blockers. Am Heart J 2000; 1139(1 pt2): 23-8.
46. Mc Kelvie RS, Yusuf S, Pericak D, Avezum A, Burns R, Probstfield J, Tsuyuki R, White M, Rouleau J, Latini R, Maggioni A, Joung J, Pogue J. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomised evaluation of strategies for the left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study investigators. Circulation 1999; 100: 1056-64.
47. Ball S. Should all patients with heart failure now receive an ACE inhibitor? Eur J Heart Fail 2001; 3: 645-6.
48. Cohn J, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
49. Farquharson CAJ, Struthers AD. Angiotensin II receptor blockers in chronic heart failure - Not as ELITE as expected! J Renin Angiotensin Aldosterone Syst 2000; 1: 21-2.
50. McMurray J, Berry C. Ongoing clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction. J Renin Angiotensin Aldosterone Syst 2000; 1: 131-6.
51. Knapp E. Impedance cardiography [in German]. Wien Klin Wochenschr Suppl 1976; 58: 1-15.
52. Horstmann E. Impedance cardiography during exercise in the evaluation of left-ventricular function [in German]. Z Kardiol 1984; 73: 374-9.
53. Löllgen H. Kardiopulmonale Funktionsdiagnostik. Edition CIBA, Wehr/Baden, 1983.